BACKGROUND: Combination chemotherapy is increasingly practiced for treating malignancies with greater sensitivity and less toxicity. Paclitaxel is a potent anti-tumor agent but has dose-limiting side-effects, whereas thalidomide is an orally active anti-angiogenic drug but less than sufficient to exert anti-tumor effect as a single agent. MATERIALS AND METHODS: Nude mice bearing hypervascular (LS174T) and less vascular (HT29) colon carcinomas were challenged with either a non-cytotoxic dose of paclitaxel, thalidomide or a combination of paclitaxel and thalidomide. RESULTS: Significant growth retardation was noticed only in the combination treatment group of LS174T tumors. Microvessel density data indicated a significantly low count in the combination treatment group compared to the others. Trends of decreased expression of angiogenic growth factors and increased apoptotic index were noticed in the combination treatment group. CONCLUSION: The results of this study underscore the therapeutic efficacy of concomitant use of paclitaxel and thalidomide in the treatment of highly vascular colorectal tumors in a xenograft model.
BACKGROUND: Combination chemotherapy is increasingly practiced for treating malignancies with greater sensitivity and less toxicity. Paclitaxel is a potent anti-tumor agent but has dose-limiting side-effects, whereas thalidomide is an orally active anti-angiogenic drug but less than sufficient to exert anti-tumor effect as a single agent. MATERIALS AND METHODS:Nude mice bearing hypervascular (LS174T) and less vascular (HT29) colon carcinomas were challenged with either a non-cytotoxic dose of paclitaxel, thalidomide or a combination of paclitaxel and thalidomide. RESULTS: Significant growth retardation was noticed only in the combination treatment group of LS174T tumors. Microvessel density data indicated a significantly low count in the combination treatment group compared to the others. Trends of decreased expression of angiogenic growth factors and increased apoptotic index were noticed in the combination treatment group. CONCLUSION: The results of this study underscore the therapeutic efficacy of concomitant use of paclitaxel and thalidomide in the treatment of highly vascular colorectal tumors in a xenograft model.
Authors: Ignasio Gil-Bazo; Ignacio Gil Bazo; Victoria Catalán Goni; Victoria Catalán González; Alvaro Alonso Gutiérrez; Javier Rodríguez Rodríguez; José Antonio Páramo Fernández; Juan de la Cámara Gómez; José Luis Hernández Lizoain; Jesús García-Foncillas López Journal: Clin Transl Oncol Date: 2005-05 Impact factor: 3.405
Authors: Christin P Hollis; Heidi L Weiss; Markos Leggas; B Mark Evers; Richard A Gemeinhart; Tonglei Li Journal: J Control Release Date: 2013-08-03 Impact factor: 9.776
Authors: Joanna Obacz; Henry Yung; Marie Shamseddin; Emily Linnane; Xiewen Liu; Arsalan A Azad; Doris M Rassl; David Fairen-Jimenez; Robert C Rintoul; Marko Z Nikolić; Stefan J Marciniak Journal: Br J Cancer Date: 2021-07-05 Impact factor: 9.075